Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 1/2013

01-01-2013 | Original Paper

Prognostic impact of pretherapeutic laboratory values in head and neck cancer patients

Authors: Franziska Peter, Claus Wittekindt, Mira Finkensieper, Michael Kiehntopf, Orlando Guntinas-Lichius

Published in: Journal of Cancer Research and Clinical Oncology | Issue 1/2013

Login to get access

Abstract

Purpose

The high comorbidity in patients with head and neck cancer (HNC) is mainly caused by the high incidence of tobacco and alcohol abuse and has direct impact on overall survival. We investigated whether HNC and its comorbidity also influence routine laboratory values and whether these values have influence on overall survival.

Methods

A retrospective cohort of 261 patients with primary squamous cell carcinoma of the oral cavity, pharynx, or larynx diagnosed between 2001 and 2006 with a complete set of pretherapeutic laboratory values was identified. The influence of standard oncological parameters, comorbidity, and each laboratory value on overall survival (OS) was investigated in univariate and multivariate analyses.

Results

Two-thirds of patients were active smokers and about one half reported high alcohol consumption. 40 % of patients had severe comorbidity according to Charlson comorbidity index. The most frequent laboratory pathologies were elevated C-reactive protein (CRP) values (66 %), impaired liver enzymes (30–50 %), decreased urea levels (33 %), leukocytosis (20 %), and anemia (10 %). In multivariate analysis for OS, a comorbidity index ≥5 (Hazard ratio [HR], 2.008; 95 % confidence interval [CI], 1.117–3.610; p = 0.020), high CRP level (HR, 2.469; CI, 1.414–4.310; p = 0.001), and abnormal low red-cell count (HR, 2.525; CI, 1.250–5.102; p = 0.010) were independent prognostic variables.

Conclusions

Comorbidity reflected by pathologic laboratory values is a major issue in HNC patients. Several pretherapeutic laboratory values have prognostic relevance for overall survival in HNC patients.
Appendix
Available only for authorised users
Literature
go back to reference Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabbeke M (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350(19):1945–1952PubMedCrossRef Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabbeke M (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350(19):1945–1952PubMedCrossRef
go back to reference Chapireau D, Adlam D, Cameron M, Thompson M (2010) Paraneoplastic syndromes in patients with primary oral cancers: a systematic review. Br J Oral Maxillofacial Surg 48(5):338–344CrossRef Chapireau D, Adlam D, Cameron M, Thompson M (2010) Paraneoplastic syndromes in patients with primary oral cancers: a systematic review. Br J Oral Maxillofacial Surg 48(5):338–344CrossRef
go back to reference Chen HH, Chen IH, Liao CT, Wei FC, Lee LY, Huang SF (2011) Preoperative circulating C-reactive protein levels predict pathological aggressiveness in oral squamous cell carcinoma: a retrospective clinical study. Clin Otolaryngol 36(2):147–153PubMedCrossRef Chen HH, Chen IH, Liao CT, Wei FC, Lee LY, Huang SF (2011) Preoperative circulating C-reactive protein levels predict pathological aggressiveness in oral squamous cell carcinoma: a retrospective clinical study. Clin Otolaryngol 36(2):147–153PubMedCrossRef
go back to reference Datema FR, Ferrier MB, van der Schroeff MP, Baatenburg de Jong RJ (2010) Impact of comorbidity on short-term mortality and overall survival of head and neck cancer patients. Head Neck 32(6):728–736PubMed Datema FR, Ferrier MB, van der Schroeff MP, Baatenburg de Jong RJ (2010) Impact of comorbidity on short-term mortality and overall survival of head and neck cancer patients. Head Neck 32(6):728–736PubMed
go back to reference D’Hoore W, Sicotte C, Tilquin C (1993) Risk adjustment in outcome assessment: the Charlson comorbidity index. Meth Inform Med 32(5):382–387PubMed D’Hoore W, Sicotte C, Tilquin C (1993) Risk adjustment in outcome assessment: the Charlson comorbidity index. Meth Inform Med 32(5):382–387PubMed
go back to reference Gaudet MM, Olshan AF, Chuang SC, Berthiller J, Zhang ZF, Lissowska J, Zaridze D, Winn DM, Wei Q, Talamini R, Szeszenia-Dabrowska N, Sturgis EM, Schwartz SM, Rudnai P, Eluf-Neto J, Muscat J, Morgenstern H, Menezes A, Matos E, Bucur A, Levi F, Lazarus P, La Vecchia C, Koifman S, Kelsey K, Herrero R, Hayes RB, Franceschi S, Wunsch-Filho V, Fernandez L, Fabianova E, Daudt AW, Dal Maso L, Curado MP, Chen C, Castellsague X, Benhamou S, Boffetta P, Brennan P, Hashibe M (2010) Body mass index and risk of head and neck cancer in a pooled analysis of case-control studies in the International Head and Neck Cancer Epidemiology (INHANCE) Consortium. Int J Epidemiol 39(4):1091–1102PubMedCrossRef Gaudet MM, Olshan AF, Chuang SC, Berthiller J, Zhang ZF, Lissowska J, Zaridze D, Winn DM, Wei Q, Talamini R, Szeszenia-Dabrowska N, Sturgis EM, Schwartz SM, Rudnai P, Eluf-Neto J, Muscat J, Morgenstern H, Menezes A, Matos E, Bucur A, Levi F, Lazarus P, La Vecchia C, Koifman S, Kelsey K, Herrero R, Hayes RB, Franceschi S, Wunsch-Filho V, Fernandez L, Fabianova E, Daudt AW, Dal Maso L, Curado MP, Chen C, Castellsague X, Benhamou S, Boffetta P, Brennan P, Hashibe M (2010) Body mass index and risk of head and neck cancer in a pooled analysis of case-control studies in the International Head and Neck Cancer Epidemiology (INHANCE) Consortium. Int J Epidemiol 39(4):1091–1102PubMedCrossRef
go back to reference Gimeno-Hernandez J, Iglesias-Moreno MC, Gomez-Serrano M, Carricondo F, Gil-Loyzaga P, Poch-Broto J (2011) The impact of comorbidity on the survival of patients with laryngeal squamous cell carcinoma. Acta Otolaryngol 131(8):840–846PubMedCrossRef Gimeno-Hernandez J, Iglesias-Moreno MC, Gomez-Serrano M, Carricondo F, Gil-Loyzaga P, Poch-Broto J (2011) The impact of comorbidity on the survival of patients with laryngeal squamous cell carcinoma. Acta Otolaryngol 131(8):840–846PubMedCrossRef
go back to reference Greve J, Schuler PJ, Bas M, Adamzik M, Brandau S, Arweiler-Harbeck D, Lang S, Hoffmann TK (2010) Coagulation factors as potential tumour markers in patients with head and neck carcinomas? Laryngorhinootol 89(10):612–615CrossRef Greve J, Schuler PJ, Bas M, Adamzik M, Brandau S, Arweiler-Harbeck D, Lang S, Hoffmann TK (2010) Coagulation factors as potential tumour markers in patients with head and neck carcinomas? Laryngorhinootol 89(10):612–615CrossRef
go back to reference Guntinas-Lichius O, Wendt T, Buentzel J, Esser D, Lochner P, Mueller A, Schultze-Mosgau S, Altendorf-Hofmann A (2010) Head and neck cancer in Germany: a site-specific analysis of survival of the Thuringian cancer registration database. J Cancer Res Clin Oncol 136(1):55–63PubMedCrossRef Guntinas-Lichius O, Wendt T, Buentzel J, Esser D, Lochner P, Mueller A, Schultze-Mosgau S, Altendorf-Hofmann A (2010) Head and neck cancer in Germany: a site-specific analysis of survival of the Thuringian cancer registration database. J Cancer Res Clin Oncol 136(1):55–63PubMedCrossRef
go back to reference Khandavilli SD, Ceallaigh PO, Lloyd CJ, Whitaker R (2009) Serum C-reactive protein as a prognostic indicator in patients with oral squamous cell carcinoma. Oral Oncol 45(10):912–914PubMedCrossRef Khandavilli SD, Ceallaigh PO, Lloyd CJ, Whitaker R (2009) Serum C-reactive protein as a prognostic indicator in patients with oral squamous cell carcinoma. Oral Oncol 45(10):912–914PubMedCrossRef
go back to reference Kruse AL, Luebbers HT, Gratz KW (2010) C-reactive protein levels: a prognostic marker for patients with head and neck cancer? Head Neck Oncol 2:21PubMedCrossRef Kruse AL, Luebbers HT, Gratz KW (2010) C-reactive protein levels: a prognostic marker for patients with head and neck cancer? Head Neck Oncol 2:21PubMedCrossRef
go back to reference Kruse AL, Luebbers HT, Gratz KW (2011) Evaluation of white blood cell count as a possible prognostic marker for oral cancer. Head Neck Oncol 3:13PubMedCrossRef Kruse AL, Luebbers HT, Gratz KW (2011) Evaluation of white blood cell count as a possible prognostic marker for oral cancer. Head Neck Oncol 3:13PubMedCrossRef
go back to reference Lee L, Cheung WY, Atkinson E, Krzyzanowska MK (2011) Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review. J Clin Oncol 29(1):106–117PubMedCrossRef Lee L, Cheung WY, Atkinson E, Krzyzanowska MK (2011) Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review. J Clin Oncol 29(1):106–117PubMedCrossRef
go back to reference Lu CC, Chang KW, Chou FC, Cheng CY, Liu CJ (2007) Association of pretreatment thrombocytosis with disease progression and survival in oral squamous cell carcinoma. Oral Oncol 43(3):283–288PubMedCrossRef Lu CC, Chang KW, Chou FC, Cheng CY, Liu CJ (2007) Association of pretreatment thrombocytosis with disease progression and survival in oral squamous cell carcinoma. Oral Oncol 43(3):283–288PubMedCrossRef
go back to reference Mell LK, Dignam JJ, Salama JK, Cohen EE, Polite BN, Dandekar V, Bhate AD, Witt ME, Haraf DJ, Mittal BB, Vokes EE, Weichselbaum RR (2010) Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol 28(1):15–20PubMedCrossRef Mell LK, Dignam JJ, Salama JK, Cohen EE, Polite BN, Dandekar V, Bhate AD, Witt ME, Haraf DJ, Mittal BB, Vokes EE, Weichselbaum RR (2010) Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol 28(1):15–20PubMedCrossRef
go back to reference Pelucchi C, Gallus S, Garavello W, Bosetti C, La Vecchia C (2008) Alcohol and tobacco use, and cancer risk for upper aerodigestive tract and liver. Eur J Cancer Prev 17(4):340–344PubMedCrossRef Pelucchi C, Gallus S, Garavello W, Bosetti C, La Vecchia C (2008) Alcohol and tobacco use, and cancer risk for upper aerodigestive tract and liver. Eur J Cancer Prev 17(4):340–344PubMedCrossRef
go back to reference Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. New Engl J Med 357(17):1705–1715PubMedCrossRef Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. New Engl J Med 357(17):1705–1715PubMedCrossRef
go back to reference Rose BS, Jeong JH, Nath SK, Lu SM, Mell LK (2011) Population-based study of competing mortality in head and neck cancer. J Clin Oncol 29(26):3503–3509PubMedCrossRef Rose BS, Jeong JH, Nath SK, Lu SM, Mell LK (2011) Population-based study of competing mortality in head and neck cancer. J Clin Oncol 29(26):3503–3509PubMedCrossRef
go back to reference Sanabria A, Carvalho AL, Vartanian JG, Magrin J, Ikeda MK, Kowalski LP (2007) Comorbidity is a prognostic factor in elderly patients with head and neck cancer. Ann Surg Oncol 14(4):1449–1457PubMedCrossRef Sanabria A, Carvalho AL, Vartanian JG, Magrin J, Ikeda MK, Kowalski LP (2007) Comorbidity is a prognostic factor in elderly patients with head and neck cancer. Ann Surg Oncol 14(4):1449–1457PubMedCrossRef
go back to reference Toro C, Rinaldo A, Silver CE, Politi M, Ferlito A (2010) Paraneoplastic syndromes in patients with oral cancer. Oral Oncol 46(1):14–18PubMedCrossRef Toro C, Rinaldo A, Silver CE, Politi M, Ferlito A (2010) Paraneoplastic syndromes in patients with oral cancer. Oral Oncol 46(1):14–18PubMedCrossRef
go back to reference van de Pol SM, Doornaert PA, de Bree R, Leemans CR, Slotman BJ, Langendijk JA (2006) The significance of anemia in squamous cell head and neck cancer treated with surgery and postoperative radiotherapy. Oral Oncol 42(2):131–138PubMedCrossRef van de Pol SM, Doornaert PA, de Bree R, Leemans CR, Slotman BJ, Langendijk JA (2006) The significance of anemia in squamous cell head and neck cancer treated with surgery and postoperative radiotherapy. Oral Oncol 42(2):131–138PubMedCrossRef
go back to reference Yung KC, Piccirillo JF (2008) The incidence and impact of comorbidity diagnosed after the onset of head and neck cancer. Arch Otolaryngol Head Neck Surg 134(10):1045–1049PubMedCrossRef Yung KC, Piccirillo JF (2008) The incidence and impact of comorbidity diagnosed after the onset of head and neck cancer. Arch Otolaryngol Head Neck Surg 134(10):1045–1049PubMedCrossRef
Metadata
Title
Prognostic impact of pretherapeutic laboratory values in head and neck cancer patients
Authors
Franziska Peter
Claus Wittekindt
Mira Finkensieper
Michael Kiehntopf
Orlando Guntinas-Lichius
Publication date
01-01-2013
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 1/2013
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-012-1320-1

Other articles of this Issue 1/2013

Journal of Cancer Research and Clinical Oncology 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.